Thanks to your support, 2024/2025 was – once more – very successful. Between 1 April 2024 and 31 March 2025, we invested almost £31 million into dementia research - our highest amount ever. This achievement is all down to the dedication of our colleagues, supporters, and partners working together for a cure.
Read the full 2024/25 Annual Report for a detailed picture of our work over the last year and the impact of our vital research.
You can also read a summary of progress made in the shorter Annual Review.
97%
of our funding comes from our incredible supporters and partners.
£30.8m
was invested in research - a 12.8% increase on last year.
46
institutions in 28 UK locations received our funding for dementia research.
3,200
researchers in 101 countries were supported by us worldwide.
800,000
people viewed our dementia information pages.
260,000
people completed our Think Brain Health Check-in last year.
FINANCIAL SUMMARY
Our previous reports
2024
2023
2022
2021
2020
At Alzheimer’s Research UK, we are committed to fairness and equality in the workplace. Our Gender Pay Gap Report provides transparency on the difference in average earnings between male and female employees and helps us track progress over time. We value all our employees and are committed to regularly reviewing our approach to ensure equal opportunities and equal treatment for all.
Alzheimer’s Research UK’s priority is to fund research that will change the lives of people affected by dementia. For every £1 donated, 71p funds vital research, helping to change the future for thousands of families.
Like our supporters Larry and Rita Woelk whose story shows how scientific progress can be turned into real hope.
Larry first noticed memory issues in 2016. An MRI in 2018 confirmed mild cognitive impairment (MCI). Soon after, he joined a clinical trial and began receiving lecanemab ,a drug to slow down the progression of Alzheimer’s disease.
Larry adds: “On lecanemab, I am still able to live a full life – going on bike rides, playing mahjong, and socialising with friends and family.”
Larry and Rita both believe the drug, which clears the protein amyloid from the brain, has helped to slow the progression of his symptoms.
Rita says: “I think to contribute to any drug trial is a gift to research. There are many people in the future who will have dementia. The more drug trials that are run, the more people who partake, the faster we will get to a cure.”
